Le Lézard
Classified in: Health, Science and technology
Subject: CCA

Implantica presents the Year-end Report (Q4 2024) on February 14 at 15:00 CET


VADUZ, Liechtenstein, Feb. 7, 2025 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the Year-end Report (Q4 2024) at 15:00 CET on February 14. The Year-end Report (Q4 2024) will be published at 8:00 a.m. CET on the same day.

The presentation will be in English via an audiocast with teleconference:

If you wish to participate via webcast, please use the following link:

If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.

Speakers:

For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
[email protected]

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, [email protected]

The information was sent for publication, through the agency of the contact person set out above, on February 7, 2025 at 2:15 p.m. CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStoptm, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/implantica/r/implantica-presents-the-year-end-report--q4-2024--on-february-14-at-15-00-cet,c4102559

The following files are available for download:

https://mb.cision.com/Main/19732/4102559/3253050.pdf

Implantica presents the Year-end Report (Q4 2024) on February 14 at 15:00 CET


These press releases may also interest you

at 05:48
Nature's Best reveal the simple fix for 4 million who struggle with tablets
Recent studies have revealed that nearly 40% of adults struggle to swallow necessary tablets and supplements. An observational study of 152 subjects examined the prevalence and contributing factors to difficulties swallowing solid oral dosage forms....

at 05:37
Emissions from trucks linked to 307,000 deaths and USD 1.4 trillion in health costs
A groundbreaking report highlights the severe health and economic impacts of diesel truck emissions globally. The study reveals diesel pollution produced by trucks from four major manufacturers has been linked to 307,000 deaths and more than USD 1.4...

at 05:34
Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines
Glenmark Pharmaceuticals Ltd. (Glenmark), a leading research-led, global pharmaceuticals company has partnered with, Health Futures Foundation, Inc. (HFI) and the Municipality of Malinao to launch a comprehensive initiative to improve nutrition among...

at 05:20
Notice to Annual General Meeting in BioInvent International AB
LUND, SE / ACCESS Newswire / March 25, 2025 / BioInvent International (STO:BINV) The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 29 April...

at 04:18
RevitaLash® Cosmetics Partners with Future Dreams and the Francis Crick Institute to Fund Groundbreaking New Breast Cancer Research
RevitaLash® Cosmetics, globally recognised for its innovative lash, brow, and hair beautification products, announces an expanded three-year partnership with the UK-based breast cancer charity Future Dreams, that incorporates the funding of a...

at 04:15
Philips demonstrates innovation power, topping European Patent Office Medtech filings in 2024
March 25, 2025 Amsterdam, the Netherlands ? Royal Philips , a global leader in health technology, today announced that in 2024 it was the leading applicant in the field of medical technology at the European Patent Office (EPO), filing 594 Medtech...

More news about Health...


News published on and distributed by: